103 related articles for article (PubMed ID: 18396444)
1. The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma.
Ma BB; Mo FK; Chan AT; Hui EP; Leung SF; Lo YM; Yau YY; King AD
Oral Oncol; 2008 Nov; 44(11):1067-72. PubMed ID: 18396444
[TBL] [Abstract][Full Text] [Related]
2. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
Ma BB; King A; Lo YM; Yau YY; Zee B; Hui EP; Leung SF; Mo F; Kam MK; Ahuja A; Kwan WH; Chan AT
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):714-20. PubMed ID: 17011447
[TBL] [Abstract][Full Text] [Related]
3. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
[TBL] [Abstract][Full Text] [Related]
4. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.
Ma B; Hui EP; King A; Leung SF; Kam MK; Mo F; Li L; Wang K; Loong H; Wong A; Chan CM; Chan KCA; Wong SCC; Lo YMD; Chan AT
Br J Cancer; 2018 Apr; 118(8):1051-1055. PubMed ID: 29555989
[TBL] [Abstract][Full Text] [Related]
6. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma.
Chan SC; Chang KP; Fang YD; Tsang NM; Ng SH; Hsu CL; Liao CT; Yen TC
Laryngoscope; 2017 Jan; 127(1):E22-E28. PubMed ID: 27435352
[TBL] [Abstract][Full Text] [Related]
7. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma.
Chen WH; Tang LQ; Zhang L; Chen QY; Guo SS; Liu LT; Fan W; Zhang X; Guo L; Zhao C; Cao KJ; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
Oncotarget; 2015 Nov; 6(35):38296-307. PubMed ID: 26512922
[TBL] [Abstract][Full Text] [Related]
8. The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma.
Chan SC; Hsu CL; Yen TC; Ng SH; Liao CT; Wang HM
Oral Oncol; 2013 Jan; 49(1):71-8. PubMed ID: 22959277
[TBL] [Abstract][Full Text] [Related]
9. Prediction of surgical outcome using plasma Epstein-Barr virus dna and (18)F-FDG PET-CT scan in recurrent nasopharyngeal carcinoma.
Chan JY; Chow VL; Mok VW; Ho AC; Wei WI
Head Neck; 2012 Apr; 34(4):541-5. PubMed ID: 21523844
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging.
Tang LQ; Chen QY; Fan W; Liu H; Zhang L; Guo L; Luo DH; Huang PY; Zhang X; Lin XP; Mo YX; Liu LZ; Mo HY; Li J; Zou RH; Cao Y; Xiang YQ; Qiu F; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Mai HQ
J Clin Oncol; 2013 Aug; 31(23):2861-9. PubMed ID: 23857969
[TBL] [Abstract][Full Text] [Related]
12. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
13. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma.
Chang KP; Tsang NM; Liao CT; Hsu CL; Chung MJ; Lo CW; Chan SC; Ng SH; Wang HM; Yen TC
J Nucl Med; 2012 Jan; 53(1):21-8. PubMed ID: 22213820
[TBL] [Abstract][Full Text] [Related]
15. Prognostic influence of parapharyngeal extension in nasopharyngeal carcinoma.
Ho HC; Lee MS; Hsiao SH; Hwang JH; Hung SK; Lee CC; Chou P
Acta Otolaryngol; 2008 Jul; 128(7):790-8. PubMed ID: 18568523
[TBL] [Abstract][Full Text] [Related]
16. [Clinical staging of nasopharyngeal carcinoma based on MRI: suggestions for improving the Chinese '92 staging system].
Mao YP; Hong MH; Sun Y; Liang SB; Li L; Liu LZ; Tang LL; Cao SM; Lin AH; Lu TX; Liu MZ; Ma J
Ai Zheng; 2007 Oct; 26(10):1099-106. PubMed ID: 17927881
[TBL] [Abstract][Full Text] [Related]
17. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Twu CW; Wang WY; Chen CC; Liang KL; Jiang RS; Wu CT; Shih YT; Lin PJ; Liu YC; Lin JC
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):21-9. PubMed ID: 24725686
[TBL] [Abstract][Full Text] [Related]
18. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
Lin JC; Wang WY; Chen KY; Wei YH; Liang WM; Jan JS; Jiang RS
N Engl J Med; 2004 Jun; 350(24):2461-70. PubMed ID: 15190138
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of post-therapy (18)F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.
Chan SC; Kuo WH; Wang HM; Chang JT; Lin CY; Ng SH; Hsu CL; Chang KP; Liao CT; Lin YJ; Yen TC
Ann Nucl Med; 2013 Oct; 27(8):710-9. PubMed ID: 23715831
[TBL] [Abstract][Full Text] [Related]
20. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
Lin JC; Wang WY; Liang WM; Chou HY; Jan JS; Jiang RS; Wang JY; Twu CW; Liang KL; Chao J; Shen WC
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1342-8. PubMed ID: 17449194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]